Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future
|
|
- Phyllis Pitts
- 6 years ago
- Views:
Transcription
1 Current Topics Advances in Immunotherapy Strategies Juntendo Medical Journal (6), Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future *1) 2) KAZUNORI KATO *1)Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan, *2) Department of Biomedical Engineering, Graduate School of Science and Engineering, Toyo University, Tokyo, Japan Monoclonal antibodies (mabs) for cancer therapy can be broadly divided into three classes. First are those that target biological features expressed by the tumor cell itself, second are those that target factors produced by the tumor cell or as a host response to the tumor, and third are those that target the immune regulatory networks responsible for inhibiting antitumor immune responses. Of these, tumor-specific therapeutic mabs are particularly unique because they partially and passively reconstitute the humoral arm of the tumor antigenspecific immune response, as well as provide critical support in establishing the antigen-specific adaptive immune response through cross-priming. This review focuses on these categories and will discuss ongoing clinical trials. Key words: monoclonal antibody, HER2, immune checkpoint, PD-1, CTLA-4 Introduction The commercial pipeline of monoclonal antibodies (mabs) is highly dynamic, with a multitude of transitions occurring during the year as product candidates advance through the clinical phase and onto the market. Rituximab (anti-cd20) and trastuzumab (anti-her2), the first mabs were approved for cancer therapy. Then two mabs were approved in use that target soluble host factors involved in the antitumor response, bevacizumab (anti-vegf) and denosumab (anti-rankl). Recently, the application of therapeutic mabs ipilimumab (anti-ctla-4) and nivolumab/pembrolizumab (anti-pd-1) that specifically target the nodal checkpoints for T-cell activation and effector function is a new area of increasing preclinical and clinical investigation. The clinical developments of mabs in various categories are described and summarized in this review (Figure-1). Monoclonal antibodies target to tumor-specific antigens 1. Trastuzumab and pertuzumab target HER2/ neupathway Trastuzumab (Herceptin ), a humanized mab specific for the human epidermal growth factor receptor 2 (HER2/neu), is widely used to treat HER2-overexpressing breast cancers at every stages except ductal carcinomas that are negative for HER2 1). Trastuzumab was first approved in 1998 and the second-generation mab pertuzumab (PERJETA ) was approved in 2012 as treatment for metastatic breast cancer. It has also been approved for the treatment of HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction. Trastuzumab has been thought to function primarily by inhibiting signal transduction via the cell surface HER2 receptor, but it can also modulate tumor immunity through multiple mechanisms. It recruits innate immune effector cells such as natural killer cells and Kazunori Kato Atopy Research Center, Juntendo University Graduate School of Medicine Hongo, Bunkyo-ku, Tokyo , Japan TEL: kzkatou@juntendo.ac.jp Received Dec. 14,
2 Kato: Therapeutic monoclonal antibodies for cancer Blockade of growth factor and its receptor Therapeutic Antibodies Targeting tumor specific Ag & drug conjugate Radioactive Drugs Effectors NK Bevacizumab Ramucirumab Denosumab Cetuximab Panitumumab Tocilizumab Figure-1 Trastuzumab Pertuzumab Rituximab Ofatumumab Ocrelizumab Obinutuzumab Mogamulizumab Treg Treg Treg Ipilimumab Nivolumab Pembrolizumab Atezolizumab Bavituximab The clinical antibodies in various therapeutic categories macrophages to the tumor microenvironment in order to facilitate antibody-dependent cellular cytotoxicity (ADCC). Trastuzumab can also induce the ubiquitination and degradation of internalized HER2 proteins, thereby increasing proteasomedependent antigen presentation on MHC molecules 2). Accordingly, it augments the cytotoxic activity of HLA Class I-restricted HER2-specific cytotoxic T lymphocytes (CTLs) against HER2positive breast cancers. In HER2-transgenic mice study, HER2 mab therapy alone induced new CD8-positive CTLs that break immune tolerance 3). In humans, a single dose of trastuzumab induced apoptosis in primary tumors within 24 hours, and trastuzumab-based neoadjuvant chemotherapy is associated with the development of T-bet-positive lymphoid nodules in patients with locally advanced breast cancer. Importantly, these lymphoid nodules are also associated with enhanced overall survival 4). Finally, chemotherapy combined with trastuzumab has been associated with the development of HER2specific CD4-positive T cell responses in patients with both early and metastatic breast cancers. The combination of low-dose cyclophosphamide, anti-her2 mab and HER2-specific peptide vaccination generated the highest numbers of HER2specific CTLs, and protected up to 70% of neu-n transgenic mice from the outgrowth of established tumors 5). These observations provide strong support for testing trastuzumab in combination with HER2 targeted vaccination inpatients with malig- 602 Inhibitor of immune checkpoint molecule nancies dependent on HER2-signaling. Two clinical trial of trastuzumab combined with vaccination have been reported. In one study, a HER2-specific T-helper peptide vaccine was combined with standard trastuzumab therapy regimen in 22 patients with metastatic breast cancer 6). This study demonstrated the safety of the combination, with about 15% of patients displaying an asymptomatic decline in cardiac ejection fraction. Immune responses against HER2 and other tumor-associated antigens were observed and the magnitude of the immune response was inversely correlated with serum TGF-beta levels, indicating the promotion immune modulating effect by the treatment with trastuzumab. In the second, the combination with trastuzumab, cyclophosphamide and GM-CSF-secreting breast cancer cell-based vaccine achieved an overall survival 40 months compared to the historical overall survival (OS) of months in similar patients who received standard trastuzumab alone 7). These clinical data strongly argues for the establishment of combination immunotherapy incorporating trastuzumab and other immune modulators such as cyclophosphamide or immune checkpoint inhibitors in patients with HER2-positive cancers. 2. Antibody-drug conjugate of trastuzumab Antibody-drug conjugates (ADCs) are becoming an increasingly important sub-class of antibodyrelated therapeutics. Trastuzumab emtansine (Kadcyle ) were recently approved for marketing
3 Juntendo Medical Journal 61 (6), 2015 Figure-2 both by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Japanese Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency (MHLW-PMDA) as a treatment for human HER2-positive breast cancer 8). Kadcyle is an ADC comprising trastuzumab linked to ImmunoGenʼ s DM1 maytansinoid drug. One of major pharmaceutical company Roche entered into licensing agreements with ImmunoGen giving rights to use ADC technology to develop therapeutics for specific targets. It is currently also undergoing evaluation in various clinical Phase trials comparing efficacies and overall survival to trastuzumab and taxane as standard regimen. 3. Rituximab and other mabs target CD20 Rituximab (Rituxan ), a chimeric mab specific for the cell surface molecule CD20 expressed by normal B cells and over 95% of B-cell leukemia and lymphoma, is widely used both as a single agent and combined with chemotherapy and radiation 9). Although the primary mechanism of action remains unclear, it has been shown to mediate ADCC, promote apoptosis, and enhance cross-priming of the adaptive immune response 10). Rituximab modulate src signaling in follicular lymphoma cells, leading to lower levels of active STAT-3 and bcl-2 and increased sensitivity to chemotherapy 11). Three clinical antibodies to HER2/erbB2 Rituximab therapy is known to result in profound B-cell depletion. B cells have been shown to inhibit tumor-specific CTL induction, suggesting that B-cell depletion in the setting of rituximab therapy may not inhibit, and could enhance, vaccineinduced tumor immunity. Based on this idea, several preclinical and clinical trials of rituximab combined with adaptive immunotherapy against B-cell malignancies have been demonstrated 12) 13). Additionally, rituximab has been indicated for the treatment of rheumatoid arthritis (RA) with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called tumor necrosis factor (TNF) antagonist has been used. Therapeutic use of rituximab for the treatment of RA is approved only by FDA and EMA but not by MHLW-PMDA in Japan so far. In recent years, new generations of anti-cd20 monoclonal antibodies (mabs) have been developed for potential benefits over the classical, first-generation mab rituximab. These second-generation mabs, which include ofatumumab, veltuzumab, and ocrelizumab, are humanized or fully human to reduce immunogenicity, but with an unmodified Fc region 14)-16). Ofatumumab is a fully human anti-cd20 IgG1 mab in clinical development for hematological malignancies and autoimmune diseases. Ofatumumab specifically recognizes an epitope encompassing both the small and large extracellular loops of CD20 molecule, and is more effective than rituximab at CDC induction and killing target cells. Veltuzumab is a humanized anti-cd20 mab with complementarity-determining regions similar to rituximab. This antibody has enhanced binding avidities and a stronger effect on CDC compared with rituximab. Ocrelizumab is a humanized mab with the potential for enhanced efficacy in lymphoid malignancies compared with rituximab due to increased binding affinity for the low-affinity variants of the FcγRIIIa receptor. Ocrelizumab is undergoing phase III clinical trials for rheumatoid arthritis and lupus nephritis, however, these clinical trial has been discontinued because of several adverse reactions at The third-generation mabs are also humanized mabs, but in addition they have an engineered Fc to increase their binding affinity for the FcγRIIIa 603
4 Kato: Therapeutic monoclonal antibodies for cancer receptor. One of anti-cd20 mab, obinutuzumab, is a fully humanized, type II, IgG1 mab derived from humanization of the parental B-Ly1 mouse antibody and subsequent glycoengineering using GlycoMab technology. Obinutuzumab was designed for enhanced ADCC and superior direct cellkilling properties, in comparison with currently available type I antibodies 17). These kinds of mabs having an engineered Fc to increase their binding affinity for the FcγRIIIa receptor will be commonly used for the treatment of not only B-cell leukemia/ lymphoma but also nonhematological malignancies. Monoclonal antibodies target to tumor microenvironment factors 1. Bevacizumab and Ramucirumab to VEGF/ VEGFR interaction Bevacizumab is a chimeric, partially humanized mab specific for the vascular endothelial growth factor (VEGF), a cytokine critical for tumorassociated angiogenesis. It is currently approved for treating colorectal cancers, glioblastomas, nonsmall cell lung carcinomas, and renal cell carcinomas. In addition to promoting neo-vessel formation, VEGF inhibits T cell developments and dendritic cells differentiation, leading to tumor-related immune suppression in cancer patients. Monoclonal antibody specific for VEGF can improve the numbers and function of dendritic cells in tumorbearing mice, thereby potentiating dendritic cellbased immune therapy 18). Bevacizumab therapy can increase the B- and T-cell subsets in cancer patients, and augment the ability of dendritic cells derived from cancer patients to stimulate T-cell responses to recall antigens. Importantly, blockades of VEGF/VEGF receptor (VEGFR) pathways can decrease macrophage and myeloid-derived suppressor cell (MDSC) infiltrating tumor tissues 19). In addition, the efficacy of adoptive cellular therapy would be synergistically enhanced by VEGF mab promoting the infiltration of transferred T cells into tumor 20). To date, one clinical trial combining bevacizumab and a cancer vaccine has been reported. Patients with metastatic prostate cancer in biochemical relapse were treated with a combination of prostatic acid phosphatase (PAP) -pulsed antigen presenting cells (APCs) and bevacizumab. All patients developed immune responses to PAP and almost half displayed some decrease in PSA from baseline, indicating that blocking of VEGF would be useful for the adjuvant immunotherapy. In order to inhibit VEGF/VEGFR interaction, several monoclonal antibodies specific for VEGF receptors have been developed. Tumor-bearing nontolerate mice treated with a specific for VEGF receptor-2 (VEGFR2) develop HER2-specific T cells, even in the absence of vaccination 21).Inthe setting of antigen-specific immune tolerance, sequencing vaccination with cyclophosphamide and doxorubicin in the setting of treatment with VEGFR2 mab unmasks the T-cell dependentactivity of the VEGFR2 mab and allows the vaccine to work, resulting in a tumor-free survival rate of about 70%. Based on these findings, ramucirumab (Cyramza ) was approved by FDA in Ramucirumab that targets human VEGFR2 is indicated for the treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine- or platinum-containing therapy. Currently, ramucirumab is undergoing regulatory review by EMA for treating gastric cancer and hepatocellular carcinoma, and also evaluation in clinical Phase III studies in patients with non-small cell lung carcinoma, colorectal cancer and breast cancer. 2. Denosumab specific for RANKL Denosumab is a mab recently approved for the management of malignant bone disease in multiple myeloma or breast cancer; it is also used to prevent fragility fractures in osteoporosis 22). This mab is specific for the signaling pathway controlled by the interactions of receptor activator of NF-kappa-B ligand (RANKL) and its antagonist osteoprotegerin. RANKL is expressed at high levels by activated T cells, and its receptor RANK is expressed by monocytes, macrophages and dendritic cells. To date, the FDA approved denosumab to prevent skeletal-related events (SREs) associated with metastatic solid tumors. Monoclonal antibodies target to immune checkpoints Recently, it has been reported various molecules contributed to immune checkpoint pathways in lymphocyte activation and differentiation. T cells 604
5 Juntendo Medical Journal 61 (6), 2015 that recognize the cognate antigen may also express a number of molecules on their surface, such as CTLA-4, PD-1, LAG-3, and BTLA. These molecules serve as checkpoints, controlling the quality and magnitude of a T-cell response. In normal circumstance, these checkpoints would act to protect the host from an overactive immune reactions and autoimmunity. In case of cancer, blockade therapy of these checkpoints could help break tolerance and could serve as to help maintain a high quality long-lasting T-cell response. The first T-cell immune checkpoint targeted for antibody blockade was CTLA-4 and then PD-1. In this chapter, the preclinical studies and clinical benefits of therapeutic mabs to CTLA-4, PD-1 and PD-L1 are introduced. 1. CTLA-4 blockade Cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152) is a negative regulator of T-cell function, and antibodies have been developed which inhibit this important immunologic checkpoint. In preclinical studies, CTLA-4 blocking antibodies were able to induce potent antitumor immunity and provided rationale for clinical use. Ipilimumab (Yervoy) a IgG1 mab against CTLA-4 and was the first drug to demonstrate an overall survival benefit for patients with melanoma in clinical Phase III trial 23). Tremelimumab is an IgG2 antibody with a plasma long half-life of approximately 3 weeks. The clinical development of ipilimumab was built upon a foundation of basic research into the mechanisms that regulate T-cell activation. The two signal model of T-cell activation was the product of fundamental studies performed in the 1970s and 1980s. In this model, antigen-specific T-cell activation requires both T-cell receptor engagement (signal 1) and a co-stimulatory signal (signal 2) for fully function, this hypothesis has been validated and expanded in the 2000s. It is now clear that a diversity of co-stimulatory and coinhibitory molecules are required to both promote and regulate the complex process of T-cell activation. Especially, CTLA-4 plays a fundamental role as an inhibitory receptor, or checkpoint, in the process of T-cell activation, such as proliferation, cytokine production and differentiation. As shown previously, CTLA-4 blocking antibody therapy in humans was developed based on the preclinical activity seen in mouse models. Both ipilimumab and tremelimumab, fully human antibodies against CTLA-4, have been most widely tested in patients with metastatic melanoma, where durable clinical responses have been well documented 24)-26). The promising results seen in Phase II studies led to Phase III evaluation. Several Phase III studies were performed and the survival benefit of ipilimumab was confirmed in a subsequent randomized Phase III trial 27). OS was significantly longer for patients who received dacarbazine with ipilimumab (11.2 mo.) than patients with dacarbazine with placebo (9.2 mo.). Based on OS in Phase III studies, FDA approved ipilimumab for the treatment of patients with unresectable or metastatic melanoma in Another Phase III study of tremelimumab was halted after an interim analysis failed to demonstrate a benefit. Expectedly, immune-related adverse effect such as colitis, dermatitis, hepatitis and endocrinopathies were observed in patients treated with ipilimumab 28).To date, a number of combination strategies of ipilimumab with novel immunotherapies or molecularly targeted therapies are likely to be promising based upon have been explored in clinical trials. At present, ipilimumab is being tested in combination with antibody to PD-1 (Nivolumab) for patients with NSCLC. 2. PD-1 and PD-L1 blockade Several other checkpoint molecules are up-regulated after the T cell and antigen-presenting cell (T/APC) interaction. These molecules help limit the T-cell response once the cells begin to migrate to tissue. This is believed to be a means of maintaining peripheral tolerance. One of important molecules, programmed cell death-1 (PD-1) is expressed by chronically activated CD4 and CD8 T cells 29). PD-1 is also significantly up-regulated on T cells present in cancerous tissues in various tumor types, including melanoma, prostate cancer 30). The PD-1-positive tumor-infiltrating T cells (TILs) exhibit an exhausted phenotype with impaired effector function compared with PD-1-negative TILs and PBLs. When PD-1 binds its ligand PD-L1 (B7-H1) or PD-L2 (B7-H2), cytokine production and T-cell activation are diminished 31). This inhibitory mechanism is present to help prevent peripheral autoimmunity. In case of tumor toler- 605
6 Kato: Therapeutic monoclonal antibodies for cancer ance, PD-1 antibody blockade may serve as a means to maintain a high level of T-cell response post DC vaccination. Two blocking monoclonal antibodies to PD-1 were just approved for clinical use in 2014 by FDA. During clinical phase studies, several drastic antitumor effects including primary and metastatic tumor sizes and overall survival were observed. Unexpectedly, the dose escalation trial showed a very low incidence of adverse events such as colitis, with only rare grade III toxicities. These autoimmune adverse events appeared to be significantly less than those noted with ipilimumab (anti- CTLA-4 blockade). Nivolumab (Opdivo) was first approved to use for the treatment of melanoma in US and has orphan drug designation in Japan. Recently, FDA has granted nivolumab Breakthrough Therapy designation for the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant and brentuximab. In addition, various clinical settings in Phase III trials are undergoing of patients with non-small cell lung carcinoma, renal cell carcinoma and head and neck squamous carcinomas. Another candidate of PD-1 mab, pembrolizumab (Keytruda), was also approved in 2014 for unresectable or metastatic melanoma and is undergoing evaluation in a Phase III study of patients with NSCLC. Additionally, therapeutic mab specific for the ligand of PD-1 (termed PD-L1 or B7-H1) is undergoing evaluation in Phase III clinical trial as treatment for NSCLC by Genentech/Roche. An Fc-engineering anti-pd-l1 mab, MPDL3280A, has been compared with docetaxel in patients with locally advanced or metastatic NSCLC who have failed platinum therapy. Another PD-L1 mab MED14736 contains three mutations in Fc portion that abrogates Fc-mediated effector function. After review and approval, these mabs will be delivered in clinical setting soon. 3. New candidates of immune checkpoint inhibitor Base on the success of PD-1 and CTLA-4 mabs, several new mab candidates have entered clinical phase studies. One of promising therapeutic mab, bavituximab, which recognize phosphatidyl-serine (PS) on tumor cells and endothelial cells in tumor microenvironments. PS is normally expressed inner cell membrane and known as Eat-me-signal molecule that is recognized by phagocytes. After the irradiation or treatment of anti-cancer drugs, PS is reversed to express outside of cell membrane of various tumor cells and endothelial cells 32). Bavituximab, chimeric IgG1 mab, was given US Fast Track designation of NSCLC. The clinical Phase III study of bavituximab plus docetaxel vs. docetaxel alone in patients with late-stage nonsquamous NSCLC began recruiting patients in Another target molecule related in immune checkpoint is the lymphocyte activating gene-3 (LAG-3) 33). Antibody specific to LAG-3 was designed and generated by Bristol-Myers Squibb. The purpose of this study is to characterize the safety, tolerability, dose limiting toxicities and maximum tolerated dose of BMS (code number of anti-lag3) administered to subjects with relapsed or refractory chronic lymphocytic leukemia (CLL), lymphomas and multiple myeloma (MM), and Phase I trial just began to recruit patients with CLL. Summary Antibody therapeutics are generally recognized as having higher phase transition rates compared with small molecules drugs, but nonetheless discontinuations do occur. The development of biological drugs such as therapeutic antibodies is a timeconsuming, risky business. Canonical therapeutics antibodies such as tumor-targeting antibodies, which are the majority of clinical approved antibodies, thus have less approval success rate of 23% compared with those for antibody-drug conjugates (ADCs) of 35%. The success rate will be increased by novel techniques of the antibody engineering and cultivation of a better understanding of biological functions of both target molecules and therapeutic antibodies in the future. References 1) Vogel CI, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agents in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002; 20: ) Varchetta S, Gibelli N, Oliviero B, et al: Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary 606
7 Juntendo Medical Journal 61 (6), 2015 operable breast cancer overexpressing Her2. Cancer Res, 2007; 67: ) Castilleja A, Ward NE, O'Brian CA, et al: Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem, 2001; 217: ) zum Büschenfelde CM, Hermann C, Schmidt B, et al: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res, 2002; 62: ) Wolpoe ME, Lutz ER, Ercolini AM, et al: HER-2/neuspecific monoclonal antibodies collaborate with HER-2/ neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8 + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol, 2003; 171: ) Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol, 2009; 27: ) Chen G, Gupta R, Petrik S, et al: A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSFsecreting breast tumor vaccine for HER2 + metastatic breast cancer. Cancer Immunol Res, 2014; 2: ) Amiri-Kordestani L, Blumenthal GM, Xu QC, et al: FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res, 2014; 20: ) Cartron G, Watier H, Golay J, et al: From the bench to the bedside: ways to improve rituximab efficacy. Blood, 2004; 104: ) Selenko N, Maidic O, Draxier S, et al: CD20 antibodyinduced apoptosis pf lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8 + cytotoxic T cells. Leukemia, 2001; 15: ) Vega MI, Huerta-Yepaz S, Garban H, et al: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene, 2004; 23: ) Neelapu SS, Kwak LW, Kobrin CB, et al: Vaccineinduced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med, 2005; 11: ) Hilchey SP, Hyrien O, Mosmann TR, et al: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of rituximab. Blood, 2009; 113: ) Robak T, Robak E: New anti-cd20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs, 2011; 25: ) Goldenberg DM, Morschhauser F, Wegener WA: Veltuzumab (humanized anti-cd20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma, 2010; 51: ) Kausar F, Mustafa K, Sweis G, et al: Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther, 2009; 9: ) Illidge T, Klein C, Sehn LH, et al: Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treat Rev, 2015; 41: ) Gabrilovich DI, Ishida T, Nadaf S, et al: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogeneous dendritic cell function. Clin Cancer Res, 1999; 5: ) Roland CI, Dineen SP, Lynn KD, et al: Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther, 2009; 8: ) Shrimali RK, Yu Z, Theoret MR, et al: Antiangiogenic agents can increase lymphocytes infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res, 2010; 70: ) Manning EA, Ullman JG, Leatherman JM, et al: A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immnunebased mechanism. Clin Cancer Res, 2007; 13: ) Body JJ: Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther, 2012; 12: ) Hodi FS, Oʼ Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010; 363: ) Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocytesassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 2003; 100: ) Ribas A, Camacho LH, Lopez-Berestein, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocytesassociated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol, 2005; 23: ) Weber JS, OʼDay S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol, 2008; 26: ) Ribas A, Hauschild A, Kefford R, et al: Phase III, openlabel, randomized, comparative study of tremelimumab and chemotherapy in patients with advanced melanoma. J Clin Oncol, 2008; 26s: LBA ) Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol, 2013; 31: ) Ishida Y, Agata Y, Shibahara K, et al: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 1992; 11: ) Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and functionally impaired. Blood, 2009; 114: ) Butte MJ, Keir ME, Phamduy TB, et al: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 2007; 27: ) Marconescu A, Thorpe PE: Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochim Biophys Acta, 2008; 1778: ) Durham NM, Nirschl CJ, Jackson CM, et al: Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One, 2014; 9: e
IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationBases for Immunotherapy in Multiple Myeloma
Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationCancer Immunotherapy Future from the Past?
Disclaimer This talk is intended for educational value, and includes comments on unlicensed drugs. Please liaise with a specialist if you have a clinical query. Cancer Immunotherapy Future from the Past?
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationCANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL
FARMAFORUM 2015 FACULTAD FARMACIA CANCER IMMUNOTHERAPY Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL The immune response to tumors Oncogenic event The immune
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationTargeting Oncogenic Drivers
Targeting Oncogenic Drivers Yujie Zhao Alex A. Adjei Department of Medicine, Roswell Park Cancer Institute, Buffalo, N.Y., USA Abstract Cancer is a genetic disease caused by a series of somatic and/or
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationHarnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms
Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms (the language of immunology) Barbara K. Dunn NCI/Division of Cancer Prevention October 23, 2017 Harnessing the Immune System
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCANCER IMMUNOTHERAPY: A REVIEW
SUMMARY CANCER IMMUNOTHERAPY: A REVIEW Nguyen Thi Kim Tran 1 ; Nguyen Thanh Minh 2 ; Jake Chen 2 The Nobel Prize in Physiology or Medicine signifies that cancer immunotherapy is becoming the most promising
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationEnhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington
Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationNobel Prize in Physiology or Medicine 2018
Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationAllergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationThe Emerging Role of Immunotherapy in Cancer Care Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky
The Emerging Role of Immunotherapy in Cancer Care 2015 Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky Renato V. La Rocca, MD, FACP I have no conflicts to disclose with respect
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationIndex. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationEvaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors
Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors Tibor Keler, PhD Chief Scientific Officer Enhancing immunity with immune modulating
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More information